Novo enters into U.S. agreement

The pharmaceutical company Novo Nordisk has entered into a collaboration in the United States, which will initially cost the Danish giant more than ten billion kroner, according to a press release. The collaborations that have been entered into with the companies Omega Therapeutics and Cellarity, will strengthen Novo’s obesity treatment methods. Novo already has a similar collaboration with Flagship Pioneering. The Danish company will cover the costs of research and development of any products. At the same time, the Danish company will pay up to USD532 million to each company upfront. In total, this corresponds to DKK 10.9 billion. /ritzau/